Harry Paul Erba, MD, PhD

Fenaux P et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020;382(2):140-51. Abstract

Garcia-Manero G et al. Oral cedazuridine/decitabine for MDS and CMML: A phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood 2020;136(6):674-83. Abstract

Sallman DA et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol 2021;39(14):1584-94. Abstract

Alice S Mims, MD, MSCR

Short NJ et al. A triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia: Results from a phase I/II study. ASH 2021;Abstract 696.

Chan LN et al. Leveraging pathway-interference to overcome drug-resistance in acute lymphoblastic leukemia. ASH 2021;Abstract 616.

Montesinos P et al. AGILE: A global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. ASH 2021;Abstract 697.

Alexander Perl, MD

DiNardo CD et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383(7):617-29. Abstract

Pollyea DA et al. Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with IDH 1/2 mutations. ASH 2020;Abstract 461.

Pratz KW et al. Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine. EHA 2021;Abstract S137.

Richard M Stone, MD

Baron F et al. Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients. Haematologica 2020;105(1):e13-6. Abstract

DiNardo C et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol 2021;39(25):2768-78. Abstract

Wei AH et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 2020;383(26):2526-37. Abstract

Geoffrey L Uy, MD

Kim K et al. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer 2021;127(20):3772-81. Abstract

Lancet JE et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 2021;8(7):e481-91. Abstract

Sallman DA et al. The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: Phase 1b results. ASH 2020;Abstract 330.